NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.

The financial website Wallethub compared all 50 states and the District of Columbia to rank the most overweight and obese ...

Novo Nordisk filed an FDA application for weekly CagriSema after trials showed up to 22.7% weight loss versus placebo.

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

A major review in Frontiers in Science highlights how tackling unsustainable food systems—reflected by our changing food ...

“Early intervention would be lifestyle change, and that can be extremely helpful, especially in younger adolescents who are ...

Once-weekly tirzepatide is associated with clinically relevant reductions in SUA levels over 72 weeks, largely driven by substantial weight loss.

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 ...

What you need to know In England, 1 in 4 adults,1 and almost 1 in 4 children by the time they are 11 years old,2 are living with obesity (based on body mass index (BMI) measurements and classification ...

Children born to mothers with prepregnancy obesity face a higher risk for neurodevelopmental disorders (ie, epilepsy).

In a real-world registry study of adults with overweight or obesity, 5:2 intermittent fasting and daily calorie restriction ...